Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases

Journal of Pharmacological Sciences

Volumn 117, Issue 4, 2011, Pages 213-222

  Fujio, Yasushi ^a   Maeda, Makiko ^a   Mohri, Tomomi ^a   Obana, Masanori ^a   Iwakura, Tomohiko ^a   Hayama, Akiko ^a   Yamashita, Tomomi ^a   Nakayama, Hiroyuki ^a   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Glycoprotein 130 (gp130); Interleukin 11 (IL 11); Interleukin 6 (IL 6); JAK STAT; STAT3

Indexed keywords

CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 11; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN;

ANGIOGENESIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; DRUG TARGETING; ENZYME ACTIVATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84855702837     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R05CR     Document Type: Review

References (74)

1. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh S-M, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995;92:1142-1146.
2. Pennica D, Shaw KJ, Swanson TA, Moor MW, Shelton DL, Zioncheck KA, et al. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem. 1995;271:10915-10922.
3. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-1254.
4. Kunisada K, Hirota H, Fujio Y, Matsui H, Tani K, Yamauchi-Takihara K, et al. Activation of Jak-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation. 1996;94:2626-2632. (Pubitemid 26403595)
5. Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T, et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem. 1998;273:9703-9710. (Pubitemid 28183061)
6. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano M, et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 1999;84:1127-1136. (Pubitemid 29244774)
7. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330-1333. (Pubitemid 47281433)
8. Haider KH, Idris NM, Kim HW, Ahmed RP, Shujia J, Ashraf M. MicroRNA-21 is a key determinant in IL-11/Stat3 anti-apoptotic signalling pathway in preconditioning of skeletal myoblasts. Cardiovasc Res. 2010;88:168-178.
9. Thum T, Gross C, Fielder J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-984.
10. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120: 3912-3916.
11. Hishinuma S, Funamoto M, Fujio Y, Kunisada K, Yamauchi-Takihara K. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun. 1999; 264:436-440. (Pubitemid 29516105)
12. Funamoto M, Hishinuma S, Fujio Y, Matsuda Y, Kunisada K, Oh H, et al. Isolation and characterization of the murine cardiotrophin-1 gene. J Mol Cell Cardiol. 2000;32:1275-1284.
13. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, et al. Cardiortrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996;271:9535-9545.
14. Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima Y, et al. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res. 2003;93: 221-229. (Pubitemid 36993233)
15. Pradervand S, Yasukawa H, Muller OG, Kjekshus H, Nakamura T, Amand TRS, et al. Small proline-rich protein 1A is a gp130 pathway- and stress-inducible cardioprotective protein. EMBO J. 2004;23:4517-4525. (Pubitemid 39601976)
16. i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol. 2007; 43:710-716.
17. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000; 101:660-667. (Pubitemid 30094738)
18. Bhuiyan MS, Fukunaga K. Cardioprotection by vanadium compounds targeting Akt-mediated signaling. J Pharmacol Sci. 2009; 110:1-13.
19. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and bcl-xL/caspase-3 interaction. Circulation. 2001;103:555-561. (Pubitemid 32116241)
20. Kimura R, Maeda M, Arita A, Oshima Y, Obana M, Ito T, et al. Identification of cardiac myocytes as targets of interleukin-11, a cardioprotective cytokine. Cytokine. 2007;38:107-115. (Pubitemid 47077909)
21. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J Biol Chem. 1997;272:5783-5791.
22. Hirota H, Chen J, Betz UAK, Rajewsky K, Gu Y, Ross JJ, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189-198. (Pubitemid 29194270)
23. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest. 1997;99:2898-2905. (Pubitemid 27278666)
24. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98: 295-303. (Pubitemid 29380565)
25. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115. (Pubitemid 29077388)
26. -/- mice: a direct role for Stat5 in bcl-XL induction. Cell. 1999;98: 181-191.
27. Xuan Y-T, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A. 2001;98:9050-9055. (Pubitemid 32743867)
28. Dawn B, Xuan Y-T, Guo Y, Rezazadeh A, Stein AB, Hunt G, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004;64:61-71. (Pubitemid 39208923)
29. Xuan Y-T, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol. 2003;35:525-537. (Pubitemid 36539458)
30. Xuan Y-T, Guo Y, Zhu Y, Wang O-L, Rokosh G, Messing RO, et al. Role of the protein kinase C-e-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation. 2005;112: 1971-1978. (Pubitemid 41377416)
31. Negoro S, Kunisada K, Fujio Y, Darville MI, Eizirik DL, Funamoto M, et al. Activation of signal transducer and activator of transcription 3 protects cardiac myocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation. 2001;104:979-981. (Pubitemid 32803871)
32. Oshima Y, Fujio Y, Nakanishi T, Itoh N, Yamamoto Y, Negoro S, et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res. 2005;65:428-435. (Pubitemid 40082485)
33. Zhao Z-Q. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol. 2004;4:159-165. (Pubitemid 38444051)
34. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 2000;275: 10561-10566. (Pubitemid 30202121)
35. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, et al. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem. 2002;277:6676-6681. (Pubitemid 34968469)
36. Carmeliet P, Ng Y-S, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med. 1999;5:495-502. (Pubitemid 29220207)
37. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-2008. (Pubitemid 34270888)
38. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43-49. (Pubitemid 40215836)
39. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521-1529. (Pubitemid 36682359)
40. Suganami E, Takagi H, Ohashi H, Suzuma K, Suzuma I, Oh H, et al. Leptin stimulates ischemia-induced retinal neovasculation: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes. 2004;53:2443-2448. (Pubitemid 39145601)
41. Wei D, Le X, Zheng L, Wang L, Frey J-A, Cao AC, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic angiogenesis and metastasis. Oncogene. 2003;22:319-329. (Pubitemid 36194328)
42. Gray ML, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, et al. HIF-1a, STAT3, CBP/p300 and Ref/APE are components of a transcriptional comples that regulates Src-dependednt hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005;24:3110-3120. (Pubitemid 40695080)
43. Jung JE, Lee H-G, Cho I-H, Chung DH, Yoon S-H, Yang YM, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal cardinoma cells. FASEB J. 2005; 19:1296-1298. (Pubitemid 41113728)
44. Jacoby JJ, Kalinowski A, Liu M-G, Zhang SS-M, Gao Q, Chai G-X, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A. 2003; 100:12929-12934. (Pubitemid 37340002)
45. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004;95:187-195. (Pubitemid 38988685)
46. Wegrzyn J, Potla R, Chwae Y-J, Sepuri NBV, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323:793-797.
47. Qiu H, Lizano P, Laure L, Sui X, Rashed E, Park JY, et al. H11 kinase/heat shock protein 22 deletion impairs both nuclear and mitochondrial functions of STAT3 and accelerates the transtion into heart failure on cardiac overload. Circulation. 2011;124: 406-415.
48. Szczepanek K, Chen Q, Derecka M, Salloum FN, Zhang Q, Szelag M, et al. Mitochondrial-targeted signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem. 2011;286: 29610-29620.
49. Phillips D, Reilley MJ, Aponte AM, Wang G, Boja E, Gucek M, et al. Stoichiometry of STAT3 and mitochondrial proteins: implications for the regulation of oxidative phosphorylation by protein-protein interaction. J Biol Chem. 2010;285:23532-23536.
50. Oh H, Bradfute SB, Gallardo T, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100:12313-12318. (Pubitemid 37271557)
51. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem. 2004;279:11384-11391. (Pubitemid 38401637)
52. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-776. (Pubitemid 37186770)
53. + cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647-653.
54. Mohri T, Fujio Y, Maeda M, Ito T, Oshima Y, Uozumi Y, et al. Leukemia inhibitory factor induces endothelial differentiation in cardiac stem cells. J Biol Chem. 2006;281:6442-6447. (Pubitemid 43847576)
55. Mohri T, Fujio Y, Obana M, Iwakura T, Matsuda K, Maeda M, et al. Signals through glycoprotein 130 regulate the endothelial differentiation of cardiac stem cells. Arterioscler Thromb Vasc Biol. 2009;29:754-760.
56. Iwakura T, Mohri T, Hamatani T, Obana M, Yamashita T, Maeda M, et al. STAT3/Pim-1 signaling pathway plays a crucial role in endothelial differentaiation of cardiac resident Sca-1+ cells both in vitro and in vivo. J Mol Cell Cardiol. 2011;51:207-214.
57. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37:726-730. (Pubitemid 40202995)
58. Shirogane T, Fukada T, Muller JMM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999;11:709-719. (Pubitemid 30030710)
59. Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood. 2004;103:4536-4544. (Pubitemid 38745981)
60. Fischer KM, Cottage CT, Wu W, Din S, Gude NA, Avitabile D, et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation. 2009;120:2077-2087.
61. Cottage CT, Bailey B, Fischer KM, Avitabile D, Collins B, Tuck S, et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res. 2010;106:891-901.
62. Hoch M, Fischer P, Stapel B, Missol-Kolka E, Sekkali B, Scherr M, et al. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell. 2011;9:131-143.
63. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation. 2003;107:798-802. (Pubitemid 36241034)
64. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopcthy. Cell. 2007;128:589-600. (Pubitemid 46206082)
65. Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O'Hara RM Jr, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci U S A. 1990;87:7512-7516. (Pubitemid 20341746)
66. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615-3624. (Pubitemid 26129589)
67. Kaye JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells. 1998;16 Suppl 2:207-223.
68. Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther. 2002;16:399-406. (Pubitemid 34214518)
69. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19:237-241. (Pubitemid 39335083)
70. Kirkiles-Smith NC, Mahboubi K, Plescia J, McNiff JM, Karras J, Schechner JS, et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. J Immunol. 2004;172:1391-1396. (Pubitemid 38116780)
71. Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, et al. Therapeutic activation of STAT3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 2010;121:684-691.
72. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145-155.
73. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure. Circulation. 2001;103:2055-2059.
74. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J. 2003; 17:2118-2120.